Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer
Evaluation of the Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine, Cisplatin, and Sintilimab as First-Line Therapy for Unresectable Biliary Tract Cancer: A Prospective, Multicenter, Randomized Controlled Study
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Feng Shen
- 電話番号:+86 13901651428
- メール:shenfengehbh@sina.com
研究場所
-
-
-
Shanghai、中国、201805
- Eastern Hepatobiliary Surgery Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Patients voluntarily provide written informed consent, with authorization obtained from the patient or legal representative prior to any protocol-related procedures.
- Age ≥ 18 years and ≤ 75 years; both female and male
- Histologically or cytologically confirmed, unresectable advanced or metastatic adenocarcinoma of biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder carcinoma.
- No prior systemic anti-tumor treatment for BTC. Patients who developed recurrent disease >6 months after surgery with curative intent and, if given, >6 months after the completion of neo/adjuvant therapy (chemotherapy and/or radiation) will be eligible.
- At least 1 lesion that qualifies as a RECIST 1.1 Target Lesion (TL) at baseline.
- ECOG performance status of 0 or 1.
- Life expectancy ≥12 weeks.
Adequate organ and bone marrow function within 14 days prior to initiation of study treatment, defined as follows:
a.Hematology (without transfusion, granulocyte colony-stimulating factor [G-CSF], or other correction treatment within 14 days prior to screening): i.Hemoglobin [HB] ≥ 90 g/L; ii.Absolute neutrophil count [ANC] ≥ 1.5 × 109/L; iii.platelet count (PLT) ≥ 75 × 109/L b.Biochemistry Examination (without albumin infusion within 14 days prior to screening): i.Total bilirubin (TBIL) ≤ 2 × upper limit of normal (ULN) (for patients with Gilbert's syndrome, ≤ 3 × ULN) ii.alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN; iii.serum creatinine (Cr) ≤ 1.5 × ULN or clearance of creatinine (CCr) ≥ 50 mL/min (Cockcroft-Gault formula);
- Male: Creatinine clearance rate = [(140 - age) × weight] / (72 × serum Cr)
- Female: Creatinine clearance rate= [(140 - age) × weight] / (72 × serum Cr) × 0.85 (Weight unit: kg; serum Cr unit: mg/dL)
- Patients with evidence of hepatitis B virus (HBV) infection, defined as detectable HBV DNA (≥10 IU/mL or above the lower limit of detection according to local laboratory standards) and positive HBsAg and/or anti-HBc, must receive antiviral therapy prior to study drug administration in accordance with institutional practice to ensure adequate viral suppression. Antiviral therapy must be continued throughout the study period and for at least 6 months after the last dose of study treatment. Patients who are anti-HBc positive but HBV DNA negative (<10 IU/mL or below the lower limit of detection according to local laboratory standards) are not required to receive antiviral therapy unless HBV DNA rises to ≥10 IU/mL or exceeds the local lower limit of detection during study treatment.
- Female patients of childbearing age must have a documented negative urine or serum pregnancy test within 7 days prior to the first dose. If the urine test result is inconclusive, a serum test must be performed, and the serum result will be considered definitive. Female patients of childbearing age who have sexual intercourse with non-sterilized male partners must agree to take effective contraceptive measures throughout the treatment and 120 days after the last dose.
- Male patients with female sexual partners of childbearing age must agree to take effective contraceptive measures throughout the treatment and 120 days after the last dose. The decision to discontinue contraception beyond this time frame should be discussed with the investigator.
- Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study requirements.
Exclusion Criteria:
- Histologically or cytologically confirmed rare biliary tract tumors, including ampullary cancer, neuroendocrine tumors, sarcoma, or mucinous cystic neoplasms.
- Other active malignancy within the past 5 years or concurrent, except adequately treated cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin.
- History of carcinomatous meningitis or brain metastases.
- Known hypersensitivity or allergic reaction to any study drug or any excipient therein.
- Participation in another investigational drug clinical trial within the past 3 months or concurrent enrollment in another clinical study, unless observational, non-interventional, or follow-up phase of an interventional study.
- Uncontrolled concurrent illness, including but not limited to moderate to severe ascites, uncontrolled or moderate-to-large pleural or pericardial effusion, uncontrolled acute or chronic pancreatitis, active hemorrhagic disorder, or severe chronic gastrointestinal disease associated with diarrhea.
- History of allogeneic organ or allogeneic bone marrow transplantation.
History of significant cardiovascular or cerebrovascular disease, including:
- congestive heart failure (NYHA Class ≥II), unstable angina, myocardial infarction, uncontrolled arrhythmia, or cerebrovascular accident within 12 months prior to first dose;
- left ventricular ejection fraction <50%;
- corrected QT interval (QTc) >480 ms (Fridericia formula);
- poorly controlled hypertension (systolic ≥150 mmHg or diastolic ≥100 mmHg based on ≥2 measurements);
- history of hypertensive crisis or hypertensive encephalopathy.
- Active autoimmune disease within 2 years prior to first dose or history of autoimmune disease with potential for relapse, including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, colitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism (except hypothyroidism controlled by hormone replacement therapy).
- Prior anti-cancer therapy-related adverse events not recovered to Grade ≤1 or baseline, with Grade ≤2 neuropathy possibly eligible per investigator assessment.
- Active infection, including tuberculosis or human immunodeficiency virus (HIV).
- Diagnosis of immunodeficiency, or chronic systemic steroid therapy (daily dose >10 mg prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to first dose of study intervention.
- History of gastrointestinal bleeding within 6 months prior to study treatment, documented predisposition to gastrointestinal hemorrhage, or known hereditary or acquired bleeding (e.g., coagulopathy) or thrombotic tendency.
- Major surgery (excluding biopsy) with incomplete recovery from surgery or surgical complications, or incomplete wound healing, prior to start of study intervention, or anticipated need for major surgery during the study period.
- Receipt of live attenuated vaccine within 28 days prior to first dose of study intervention, or anticipated need for live attenuated vaccine during study treatment or within 60 days after last dose.
- Any other condition judged by the investigator to potentially interfere with study outcomes or lead to premature study termination, including alcohol or drug abuse, severe comorbidity requiring concomitant therapy (including psychiatric illness), severe laboratory abnormality, or family or social factors affecting patient safety or data collection.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:SBRT+sintilimab+GC
SBRT: total dose of 35 Gy in 5 fractions (7 Gy per fraction); Followed by Sintilimab (200 mg, iv, d1, q3w) in combination with gemcitabine (1000 mg/m², iv, d1/d8, q3w), cisplatin (25 mg/m², iv, d1/d8, q3w)
|
Participants receive sintilimab (200 mg, intravenous [IV], day 1), gemcitabine (1000 mg/m², IV, day 1 and day 8), and cisplatin (25 mg/m², IV, day 1 and day 8) every 3 weeks (q3w).
The drugs are administered sequentially with an interval of >30 minutes between each, preferably on the same day.
Different drugs require separate infusion bags and filters.
Stereotactic body radiotherapy (SBRT) is delivered only to participants in the experimental arm with total dose of 35 Gy in 5 fractions (7 Gy per fraction).
SBRT is completed within 1 week before the first cycle of sintilimab+GC.
|
|
アクティブコンパレータ:sintilimab+GC
Sintilimab (200 mg, iv, d1, q3w) combined with gemcitabine (1000 mg/m², iv, d1/d8, q3w) and cisplatin (25 mg/m², iv, d1/d8, q3w)
|
Participants receive sintilimab (200 mg, intravenous [IV], day 1), gemcitabine (1000 mg/m², IV, day 1 and day 8), and cisplatin (25 mg/m², IV, day 1 and day 8) every 3 weeks (q3w).
The drugs are administered sequentially with an interval of >30 minutes between each, preferably on the same day.
Different drugs require separate infusion bags and filters.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free Survival (PFS)
時間枠:Through out the study (up to 3 years)
|
The time from the date of randomization to the date of the first documented tumor progression as determined by the investigator (per RECIST 1.1), or death due to any cause.
|
Through out the study (up to 3 years)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free Survival (PFS)
時間枠:Through out the study (up to 3 years)
|
The time from the date of randomization to the date of the first documented tumor progression as determined by the investigator (per mRECIST), or death due to any cause.
|
Through out the study (up to 3 years)
|
|
Objevtive Response Rate (ORR)
時間枠:Tumor assessments every 6 weeks for the first 48 weeks relative to the date of randomization and then every 12 weeks thereafter. Assessed up to maximum of approximately 3 years.
|
Disease assessments based on investigator assessments were determined by using RECIST v1.1/mRECIST.
The ORR was defined as the percentage of patients with complete response (CR) or partial response (PR).
|
Tumor assessments every 6 weeks for the first 48 weeks relative to the date of randomization and then every 12 weeks thereafter. Assessed up to maximum of approximately 3 years.
|
|
Disease Control Rate (DCR)
時間枠:Tumor assessments every 6 weeks for the first 48 weeks relative to the date of randomization and then every 12 weeks thereafter. Assessed up to maximum of approximately 3 years.
|
Disease control rate based on investigator assessments according to RECIST v1.1/mRECIST was defined as the proportion of CR, PR or stable disease (SD).
|
Tumor assessments every 6 weeks for the first 48 weeks relative to the date of randomization and then every 12 weeks thereafter. Assessed up to maximum of approximately 3 years.
|
|
Time to Response (TTR)
時間枠:Through out the study (up to 3 years)
|
The time from randomization to the first evaluation of the tumor as CR, PR (per RECIST v1.1 and mRECIST).
|
Through out the study (up to 3 years)
|
|
Duration of Response (DoR)
時間枠:Through out the study (up to 3 years)
|
The time from the first evaluation of the tumor as CR, PR to the first evaluation as PD (per RECIST v1.1 and mRECIST) or death from any cause.
|
Through out the study (up to 3 years)
|
|
Overall Survival (OS)
時間枠:Through out the study (up to 3 years)
|
The time from the date of randomization until death due to any cause.
|
Through out the study (up to 3 years)
|
|
Incidence of Adverse Events (AEs)
時間枠:Through out the study (up to 3 years)
|
The incidence and severity of adverse events (AEs), serious adverse events (SAEs), immune-related adverse events (irAEs), and laboratory abnormalities, assessed according to the NCI-CTCAE v5.0.
|
Through out the study (up to 3 years)
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Feng Shen、Eastern Hepatobiliary Surgery Hospital
- 主任研究者:Ruiliang Ge、Eastern Hepatobiliary Surgery Hospital
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- EHBHKY2026-H008-P001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。